Retour sur lavenir.net
   AB INBEV 58.980 € (-0,03 %)     JENSEN-GROUP 64.400 € (-5,01 %)     UCB 247.400 € (-0,48 %)     KBC 102.950 € (-1,34 %)     BREDERODE 101.000 € (-0,39 %)     ARGENX SE 583.200 € (-0,85 %)     COFINIMMO 81.250 € (0,00 %)     FAGRON 21.500 € (-0,23 %)     AGEAS 60.050 € (+1,26 %)     D'IETEREN GROUP 157.500 € (-2,48 %)     ACKERMANS V.HAAREN 262.200 € (+0,46 %)     GBL 75.450 € (-0,46 %)     MONTEA 64.800 € (-1,07 %)     MELEXIS 50.900 € (0,00 %)     NEXTENSA 43.400 € (+1,17 %)     UMICORE 16.420 € (+4,32 %)     PROXIMUS 7.000 € (+1,16 %)     AEDIFICA 69.750 € (+0,36 %)     KBC ANCORA 69.300 € (-0,57 %)     VIOHALCO 12.620 € (-3,81 %)     SYENSQO 47.190 € (+3,97 %)     VASTNED 28.800 € (-0,35 %)     AGFA-GEVAERT 0.463 € (-0,43 %)     CIE BOIS SAUVAGE 314.000 € (-1,26 %)     TITAN S.A. 45.600 € (+0,55 %)     WDP 22.320 € (0,00 %)     WERELDHAVE BELGIUM 53.800 € (0,00 %)     HOME INVEST BE. 18.380 € (-0,33 %)     COLRUYT 34.100 € (+2,83 %)     AZELIS GROUP 7.945 € (+6,64 %)     DEME GROUP 184.800 € (+0,43 %)     BPOST 1.816 € (-0,22 %)     ONTEX GROUP 4.065 € (-1,81 %)     CMB.TECH 10.980 € (+3,00 %)     SOLVAC NOM(RETAIL) 64.400 € (-1,53 %)     VGP 84.800 € (-0,93 %)     RECTICEL 9.120 € (-2,36 %)     LOTUS BAKERIES 9 730.000 € (+1,04 %)     TESSENDERLO 24.250 € (+0,83 %)     SOLVAY 25.180 € (+0,88 %)     EKOPAK 4.230 € (-2,98 %)     XIOR 26.400 € (-0,75 %)     IBA 13.480 € (-0,74 %)     EVS BROADC.EQUIPM. 32.500 € (-0,76 %)     TUBIZE-FIN 209.000 € (-0,24 %)     CAMPINE 181.500 € (-1,36 %)     INCLUSIO SA/NV 17.200 € (-0,29 %)     ORANGE BELGIUM 20.200 € (0,00 %)     UNIFIEDPOST GROUP 3.240 € (+1,25 %)     BANQUP GROUP 3.240 € (+1,25 %)     WHAT''S COOKING GP 141.500 € (+1,07 %)     GIMV 43.750 € (0,00 %)     RETAIL ESTATES 64.800 € (+0,78 %)     NYXOAH 2.760 € (+1,85 %)     SOFINA 214.400 € (-0,92 %)     BIOTALYS 1.680 € (+1,20 %)     FLUXYS BELGIUM D 20.800 € (+1,96 %)     SEQUANA MEDICAL 0.508 € (-1,17 %)     ONWARD MEDICAL 3.480 € (-1,14 %)     SHURGARD 25.000 € (-0,60 %)  
   TELEPERFORMANCE 46.050 € (-6,99 %)     VALLOUREC 20.190 € (+2,88 %)     STMICROELECTRONICS 27.510 € (+1,89 %)     BNP PARIBAS ACT.A 82.940 € (-0,49 %)     SOCIETE GENERALE 63.520 € (-0,50 %)     AKZO NOBEL 48.940 € (+1,33 %)     SCHNEIDER ELECTRIC 241.800 € (-0,62 %)     ADYEN 888.500 € (+1,21 %)     LVMH 460.750 € (-1,25 %)     CARREFOUR 15.330 € (+2,17 %)     WINAMP GROUP 0.496 € (-6,42 %)     EXOR NV 63.500 € (-1,85 %)     ARCELORMITTAL SA 45.230 € (+2,31 %)     LEGRAND 135.500 € (+0,63 %)     SOITEC 50.700 € (-2,20 %)     CREDIT AGRICOLE 16.105 € (-0,46 %)     ORANGE 17.200 € (+1,42 %)     BE SEMICONDUCTOR 184.100 € (+0,85 %)     TOTALENERGIES 77.210 € (+1,59 %)     AHOLD DEL 40.530 € (+1,17 %)     WOLTERS KLUWER 62.560 € (-1,97 %)     SANOFI 77.770 € (+1,22 %)     ING GROEP N.V. 21.775 € (-1,43 %)     ESSILORLUXOTTICA 192.750 € (-0,16 %)     VINCI 127.350 € (+0,55 %)     CAPGEMINI 96.360 € (-1,91 %)     SHELL PLC 39.925 € (+2,90 %)     CATERING INTL SCES 13.300 € (+3,10 %)     TECHNIP ENERGIES 34.100 € (0,00 %)     EXOSENS 61.800 € (-2,06 %)     DSM FIRMENICH AG 58.940 € (+1,41 %)     HEINEKEN HOLDING 60.800 € (-0,33 %)     AXA 37.900 € (+0,08 %)     BUREAU VERITAS 26.000 € (0,00 %)     POUJOULAT 8.000 € (+2,04 %)     SAINT GOBAIN 70.420 € (-0,56 %)     BOLLORE 4.850 € (0,00 %)     ABN AMRO BANK N.V. 26.760 € (-0,41 %)     VOPAK 45.620 € (+0,53 %)     SAFRAN 282.100 € (-1,81 %)     CRCAM NORM.SEINE 131.600 € (-2,79 %)     EURONEXT 135.100 € (+1,66 %)     VIVENDI SE 1.689 € (-0,50 %)     PERNOD RICARD 62.900 € (-1,16 %)     RUBIS 33.280 € (+1,09 %)     SCOR SE 30.120 € (-0,07 %)     ARKEMA 54.300 € (+2,55 %)     NN GROUP 65.620 € (-0,36 %)     ASR NEDERLAND 58.200 € (+0,45 %)     ASML HOLDING 1 201.600 € (+2,23 %)     MOULINVEST 24.000 € (+1,69 %)     CORBION 18.340 € (+1,55 %)     TF1 6.920 € (0,00 %)     HIGH CO 3.490 € (-1,41 %)     UMG 15.465 € (-1,72 %)     WORLDLINE DS 0.560 € (-19,56 %)     BOURSE DIRECT 4.450 € (-1,98 %)     HEINEKEN 65.720 € (-0,03 %)     AALBERTS NV 30.360 € (-0,46 %)     OREGE 0.290 € (-2,68 %)  
News Réglementées
17/03/2026 13:05

Golden Helix Partners with the Austrian Human Genetics Labs to Drive Advancements in Genomic Medicine

EQS-News: Golden Helix, Inc. / Key word(s): Agreement
Golden Helix Partners with the Austrian Human Genetics Labs to Drive Advancements in Genomic Medicine

17.03.2026 / 13:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


BOZEMAN, Mont., March 17, 2026 /PRNewswire/ -- Golden Helix, a global leader in bioinformatics solutions for Next-Generation Sequencing (NGS) and precision medicine, is proud to announce a strategic agreement with the Austrian public medical genetics labs. The agreement aims to enhance the genomic capabilities of multiple laboratories within the country, supporting critical advancements in cancer and hereditary disease diagnostics.

Golden Helix Logo

In a unified effort across Austria's healthcare regions, the six designated Centres for Medical Genetics in Austria are committed to interconnecting their existing Golden Helix's high-quality genomic technologies into harmonized clinical workflows to improve patient outcomes. With a longstanding relationship spanning over a decade, this multi-year agreement solidifies the trust and commitment between Golden Helix and these institutions, driving state-of-the-art patient care in genomic medicine.

Prof. Dr. med. Zschocke, PhD, Chair of the Austrian Society of Human Genetics (ÖGH) and Professor of Human Genetics of the Medical University Innsbruck: "This agreement with Golden Helix ensures optimal access to Golden Helix's state-of-the-art NGS diagnostic capabilities. We will leverage this in routine diagnostics across all labs, as well as part of the key infrastructure of the Human Genome Project here in Austria. In that regard, the ability to run the software as a medical device in DX mode is key to our routine testing efforts. At the same time, we leverage scalable and high-performing software to run research projects on human genomes at a country-wide scale."

Dr. Laccone, Head of the Clinical Section, Institute of Medical Genetics, at the Medical University of Vienna, said: "We have been working with Golden Helix for over a decade. It is my distinct pleasure to see the relationship grow over all these years. We are excited to enter a new era of human diagnostics that includes also long-read sequencing besides our well-established tests based on short-read technology."

Andreas Scherer, PhD, President & CEO of Golden Helix, expressed his gratitude for the collaboration: "We are humbled by this incredible commitment to Golden Helix by entering into the partnership with the Austrian Medical Genetics Labs. We have over a decade of experience working with labs in that region. We are delighted to take our collaborative efforts to deliver clinical diagnostics and personalized care to the next level."

Golden Helix's software solutions are trusted by institutions worldwide, from clinical labs to research organizations, for their ability to streamline genomic data analysis and support scalable, high-quality workflows. This collaboration further underscores Golden Helix's leadership in empowering healthcare providers with tools to advance precision medicine globally.

About the Austrian Centres of Medical Genetics
Austria's public Medical Genetics system is anchored by six institutions at the Medical Universities Vienna, Innsbruck and Graz, the University Hospitals in Linz and Salzburg, Ordensklinikum Linz, and the Center for Medical Genetics at Hanusch Hospital Vienna that collaborate to support high-quality healthcare and precision medicine. These centers focus on collecting and organizing data from genetic diagnostics, integrating genome analysis and counseling into standard medical care, and contributing directly to Austria's public healthcare system. Their coordinated efforts strengthen collaboration nationwide, support European reference networks for rare diseases, and guide the development of a medically annotated variant database to improve clinical decision-making. Together, the participating centres form a unified network that advances genomic research, improves patient outcomes, and supports long-term public health in Austria.

About Golden Helix
Golden Helix has delivered trusted bioinformatics solutions for over 25 years to hospitals, testing laboratories, research institutions, and national genome programs around the world. With powerful tools for tertiary analysis and genomic warehousing, Golden Helix empowers customers to uncover disease-causing mutations, personalize treatment decisions, and empower Precision Medicine in rare disease diagnostics, oncology and pharmacogenetics.

Persephone Fossi
Marketing and Sales Associate
Golden Helix, Inc
(406) 999-0169
fossi@goldenhelix.com

Logo - https://mma.prnewswire.com/media/1227873/Golden_Helix_Logo.jpg

Cision View original content:https://www.prnewswire.com/de/pressemitteilungen/golden-helix-partners-with-the-austrian-human-genetics-labs-to-drive-advancements-in-genomic-medicine-302715388.html

rt.gif?NewsItemId=EN11126&Transmission_Id=202603170800PR_NEWS_EURO_ND__EN11126&DateId=20260317


17.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2292878  17.03.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière